KRAS Activating Mutation

CI-VAR-00000180Explore in graph →CIViC 2649

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm3
KRAS Activating Mutation	Inhibitor	Predictive	D	Supports Sensitivity Response	2	submitted	EID7182 Biochemical screening and subsequent structure-based hit optimization yielded inhibitors of the KRAS-PDEδ interaction that inhibit oncogenic RAS signalling and suppress in vitro and in vivo prolifera… (full text at CIViC) PMID 23698361 · Zimmermann et al., 2013 · Open in CIViC	civic
KRAS Activating Mutation	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Predictive	D	Supports Sensitivity Response	1	submitted	EID7184 MAP-ERK kinase (MEK) inhibition in a large PDA cell line panel. Combinations of MEK and EGFR inhibitors induced apoptosis. Combinatorial effect was observed in the epithelial but not mesenchymal subt…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.